Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company's Comprehensive Patient-Centric Solutions
Prolaris、MyRisk 和精準腫瘤檢測在各個癌症階段得到驗證,提升了公司的綜合以患者爲中心的解決方案。
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network (NCCN) as the guidelines underscore the critical role of the company's portfolio of offerings across the patient's prostate cancer journey. These guidelines further validate Myriad's ability to streamline the diagnostic process and enhance personalized treatment options.
鹽湖城,2024年12月10日(環球新聞網絡)-- 萬基遺傳公司(納斯達克:MYGN),作爲遺傳和腫瘤基因組檢測的領先者,讚揚來自國家綜合癌症網絡(NCCN)的更新前列腺癌指南,因爲這些指南強調了公司在患者前列腺癌旅程中的產品組合所扮演的關鍵角色。這些指南進一步驗證了萬基簡化診斷過程和增強個性化治療選擇的能力。
"Myriad's robust portfolio uniquely supports a patient's entire prostate cancer journey, setting us apart in the field of oncology," said George Daneker, Jr., MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. "From diagnosis to advanced treatment insights, we aim to deliver unparalleled accuracy and clarity at every stage of the disease. The updated NCCN guidelines further validate the importance of our comprehensive solutions, including diagnostic testing, multigene germline testing, and tumor molecular profiling. In addition, Myriad offers customizable workflow solutions and access to genetic experts to discuss results. Together, these empower clinicians to provide more precise and informed care for their patients."
「萬基的強大產品組合獨特地支持患者整個前列腺癌旅程,使我們在腫瘤學領域獨樹一幟,」萬基遺傳的總裁兼首席臨床官George Daneker, Jr. 醫生表示。「從診斷到先進的治療見解,我們旨在在疾病的每個階段提供無與倫比的準確性和清晰度。更新的NCCN指南進一步驗證了我們綜合解決方案的重要性,包括診斷檢測、多基因種系檢測和腫瘤分子成分分析。此外,萬基還提供可定製的工作流程解決方案以及與遺傳專家討論結果的機會。這些都使臨床醫生能夠爲他們的患者提供更精準和更具信息性的護理。」
Myriad's full suite of urologic oncology products is uniquely aligned with the updated NCCN Guidelines, offering integrated genetic and tumor genomic insights that identify germline risk, provide valuable insights into tumor biology, simplify therapy selection, and clinical trial eligibility identification for patients.
萬基的全套泌尿腫瘤學產品與更新的NCCN指南獨特對齊,提供集成的遺傳和腫瘤基因組見解,以識別種系風險,提供關於腫瘤生物學的寶貴見解,簡化治療選擇,以及患者臨床試驗資格的識別。
Included within the NCCN updates are:
NCCN更新中包括:
- Recommendations for multigene germline testing for patients with metastatic, regional (node-positive), very-high-risk localized, or high-risk localized prostate cancer, regardless of family history. MyRisk Hereditary Cancer Test evaluates 48 genes associated with hereditary cancer risk, providing critical insights to help guide treatment and management decisions as well as identify risk to family members.
- Emphasis on comprehensive management of prostate cancer, including genetic insights. Prolaris Prostate Cancer Test is a molecular diagnostic test that quantifies prostate cancer aggressiveness and helps identify optimal treatment paths, including whether to pursue or forgo treatment. It is the only biomarker test that quantifies the absolute benefit of adding ADT to RT for improved patient outcomes.
- Recommendations for tumor molecular and biomarker analysis for metastatic prostate cancer patients to inform treatment decisions. Precise Tumor Molecular Profile Test offers multigene tumor profiling, including BRCA1, BRCA2, and homologous recombination repair genes, critical for optimizing targeted therapies. Additionally, the test assesses tumor mutational burden (TMB), a key factor NCCN highlights for patients with metastatic castration-resistant prostate cancer (mCRPC), enabling more tailored immunotherapy decisions.
- 對於轉移性、區域型(淋巴結陽性)、極高風險侷限性或高風險侷限性前列腺癌患者,推薦進行多基因生殖系檢測,無論家族史如何。MyRisk遺傳癌症檢測評估48種與遺傳癌症風險相關的基因,爲治療和管理決策提供關鍵見解,同時識別對家庭成員的風險。
- 強調對前列腺癌的全面管理,包括基因見解。Prolaris前列腺癌檢測是一種分子診斷測試,量化前列腺癌的侵襲性,並幫助識別最佳治療路徑,包括是否追求或放棄治療。這是唯一一種量化將ADt添加到Rt對改善患者結果的絕對益處的生物標誌物測試。
- 針對轉移性前列腺癌患者,提供腫瘤分子和生物標誌物分析的推薦,以指導治療決策。精準腫瘤分子圖譜檢測提供多基因腫瘤譜系分析,包括BRCA1、BRCA2和同源重組修復基因,這些對優化靶向療法至關重要。此外,該檢測評估腫瘤突變負荷(TMB),這是NCCN強調的關鍵因素,適用於轉移性去勢耐藥前列腺癌患者(mCRPC),使得免疫治療決策更加個性化。
Both MyRisk and Precise Tumor focus on clinically relevant variations in the genome, where each test couples RNA analysis with DNA sequencing to provide more refined interpretation of results.
MyRisk和精準腫瘤測試都關注基因組中臨床相關的變異,各種測試將RNA分析與DNA測序結合,以提供更精細的結果解讀。
Myriad continues to invest in its full portfolio of oncology products, including Precise MRD, its molecular residual disease (MRD) assay, and other innovations to drive personalized and actionable insights for clinicians and patients.
萬基繼續投資於其完整的腫瘤學產品組合,包括精準MRD,其分子殘留病(MRD)檢測,以及其他創新,以推動爲臨床醫生和患者提供個性化和可操作的見解。
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .
關於Myriad Genetics
萬基遺傳是一家領先的基因檢測和精準醫療公司,致力於推動所有人的健康與福祉。萬基開發並提供基因檢測,幫助評估患病或病情進展的風險,並指導在醫療專業中可以顯著改善病人護理並降低醫療成本的治療決策。有關更多信息,請訪問。
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's robust portfolio and how it uniquely support a patient's entire prostate cancer journey, the company's aim to deliver unparalleled accuracy and clarity at every stage of the disease, the combination of the company's diagnostic testing, multigene germline testing, tumor molecular profiling, customizable workflow solutions, and access to genetic experts to discuss results empowering clinicians to provide more precise and informed care for their patients, and the company continues to invest in its full portfolio of oncology products, including Precise MRD and other innovations, to drive personalized and actionable insights for clinicians and patients. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
安全港聲明
本新聞稿包含1995年《私人證券訴訟改革法案》所定義的「前瞻性陳述」,包括與公司的強大投資組合相關的陳述,以及它如何獨特地支持患者整個前列腺癌歷程,公司的目標是在疾病的每一個階段提供無與倫比的準確性和清晰度,公司診斷測試、多個基因血統測試、腫瘤分子分析、可定製工作流程解決方案以及與遺傳專家討論結果的訪問相結合,使臨床醫生能夠爲患者提供更精確和更有信息的護理,而公司繼續投資於其全系列腫瘤產品,包括精確的MRD和其他創新,以推動爲臨床醫生和患者提供個性化和可操作的洞察。這些「前瞻性陳述」是管理層在本聲明之日對未來事件的預期,受到已知和未知風險和不確定性的影響,這可能導致實際結果、情況和事件與預期的發生有重大和負面的偏差。這些因素包括公司向美國證券交易委員會提交的文件中描述的風險,包括公司於2024年2月28日提交的10-K年報,以及公司不時提交的10-Q季度報告或8-K當前報告中風險因素的任何更新。萬基沒有任何義務,明確聲明不承擔任何義務,去更新或修改任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因,除非法律要求。
National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
國家綜合癌症網絡。NCCN 對其內容、使用或應用不提供任何形式的保證,並且對其應用或使用概不承擔任何責任。
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
投資者聯繫
馬特·斯卡洛
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
媒體聯繫人
格倫·法雷爾
(385) 318-3718
PR@myriad.com
譯文內容由第三人軟體翻譯。